Olivier Manigart Eur Eng MSc PhD
- Center for Vaccines Development (CVD)-Mali, Bamako, Mali
- LSHTM
- Keppel Street
- London
- WC1E 7HT
- T: +22376630122
Dr Olivier Manigart started working on HIV research in 1995 in Paris. During this period, he gained experience working on HIV diversity and mother-to-child transmission (MTCT). After an almost two years experience with Hopital Necker-Enfants Malades in Prof Christine Rouzioux’s lab and the Pasteur Institute, he joined Africa to become the lab Director of one of the sites of the first prevention of MTCT clinical trial in Africa (DITRAME) with Prof Philippe Van de Perre.
During this period, he has also been at the forefront of studies on HIV superinfections in West Africa for more than six years (Burkina Faso), and then after in East Africa (Zambia, Rwanda). He was the PI of an ANRS funded study of superinfections using an alternative tool called heteroduplex mobility assay which allowed to identify the first HIV superinfection in Africa (HMA – see paper in AIDS).
In 2004, he joined the Rwanda Zambia HIV Research Group, Emory University, Atlanta, (www.rzhrg.org) and International Aids Vaccine Initiative (www.iavi.org) and has been working on the study of HIV transmission with Prof Susan Allen and Prof Eric Hunter’s groups, to improve the quality of future vaccines.
Moreover, he was the Principal Investigator of an IAVI funded study called “a cross-sectional study to screen for and generate broadly neutralizing monoclonal antibodies from HIV infected individuals” in Zambia that led to the major discovery of two new “broad-cross neutralizing antibodies” (PG9 and PG16 – see publication in Science/Nature), and, as a Lab Director, was responsible for the implementation of several clinical and vaccine trials.
In order to improve his vaccine, immunology and molecular biology knowledge to the bacterial domain and to extend his experience to other African countries with new networks, Olivier joined the MenAfriCar consortium, and Profs Brian Greenwood and James Stuart, almost three years ago, which aims to evaluate the impact on meningos carriage in the meningitis belt of the new conjugate A vaccine developed by the Serum Institute of India, with the support of WHO and PATH (www.menafricar.org; www.meningvax.org). In this context, he is now also the PI of a Meningitis Research Foundation (MRF) funded project that has for principal objective developing new molecular biology tools to improve the diagnosis of N. meningitidis in the African context, including rare strains (http://www.meningitis.org/current-projects/development-of-a-molecular-38031).
This experience makes Olivier an expert in four major domains: molecular biology, virology, immunology and vaccines evaluation.
Affiliation
Teaching
Part time lecturer at the University of Zambia 4 hours/week during two years (Medical Microbiology – Second, third and final year).
Research
- 15 years of clinical and vaccine trials experience in Africa, 18 years of health research experience.
- Project management experience including contracts, budgets, grants, recruitments, monitoring and evaluation.
- Expertise in HIV Research.
- Expertise in molecular biology, serology and GCLP.
- Laboratory implementation, development, evaluation and follow-up according to Good Clinical and Laboratory Practices (GCLP).
- Public health, community development, capacity-building.
- Management experience of several teams in different contexts.
- Knowledge working with funders, particularly BMGF, Wellcome Trust, IAVI, ANRS and universities.
- Training and teaching experience both in English and French.
- Routine and advanced laboratory technologies including haematology, biochemistry, HIV, malaria, TB diagnosis and patients’ follow-up techniques (Microscopy, rapid tests, PCR, flow-cytometry, etc...).
- Led several labs to accreditation by different institutions (Qualogy- UK, PPD – SA).
- Principal Investigator for several research project s (Agence Nationale de Recherche contre le Sida et les hepatites, ANRS - France, International Aids Vaccine Initiative, IAVI - USA, Meningitis Research Foundation, MRF – UK)
- Proficient for Excel, Winword, Powerpoint …etc. (both PC and Macintosh platforms) + many other phylogenetic analyses programs.
- Long experience of working with community-based associations.
Research areas
- Health sector development
- Vaccines
Disciplines
- Genetic epidemiology
- Immunology
- Microbiology
- Molecular biology
Disease and Health Conditions
- Infectious disease
- Meningitis
Other interests
- Dynamic Of HIV Molecular Biology And Superinfections
-
Selected publications
-
Broad neutralization coverage of HIV by multiple highly potent antibodies.
Walker, L.M. ; Huber, M. ; Doores, K.J. ; Falkowska, E. ; Pejchal, R. ; Julien, J.P. ; Wang, S.K. ; Ramos, A. ; Chan-Hui, P.Y. ; Moyle, M. ; Mitcham, J.L. ; Hammond, P.W. ; Olsen, O.A. ; Phung, P. ; Fling, S. ; Wong, C.H. ; Phogat, S. ; Wrin, T. ; Simek, M.D. ; Protocol G Principal Investigators,(inc Manigart, O;) . ; Koff, W.C. ; Wilson, I.A. ; Burton, D.R. ; Poignard, P. ;
Nature, 2011; 477(7365):466-70
-
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1.
Haaland, R.E.; Hawkins, P.A.; Salazar-Gonzalez, J.; Johnson, A.; Tichacek, A.; Karita, E.; Manigart, O.; Mulenga, J.; Keele, B.F.; Shaw, G.M.; Hahn, B.H.; Allen, S.A.; Derdeyn, C.A.; Hunter, E.;
PLoS Pathog, 2009; 5(1):e1000274
-
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
Simek, M.D.; Rida, W.; Priddy, F.H.; Pung, P.; Carrow, E.; Laufer, D.S.; Lehrman, J.K.; Boaz, M.; Tarragona-Fiol, T.; Miiro, G.; Birungi, J.; Pozniak, A.; McPhee, D.A.; Manigart, O.; Karita, E.; Inwoley, A.; Jaoko, W.; Dehovitz, J.; Bekker, L.G.; Pitisuttithum, P.; Paris, R.; Walker, L.M.; Poignard, P.; Wrin, T.; Fast, P.E.; Burton, D.R.; Koff, W.C.;
J Virol, 2009; 83(14):7337-48
-
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Walker, L.M.; Phogat, S.K.; Chan-Hui, P.Y.; Wagner, D.; Phung, P.; Goss, J.L.; Wrin, T.; Simek, M.D.; Fling, S.; Mitcham, J.L.; Lehrman, J.K.; Priddy, F.H.; Olsen, O.A.; Frey, S.M.; Hammond, P.W.; Protocol G Principal Investigators (Miiro G, Serwanga J, Pozniak A, McPhee D; Manigart, O; Mwananyanda L, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Allen S,);, .; Kaminsky, S.; Zamb, T.; Moyle, M.; Koff, W.C.; Poignard, P.; Burton, D.R.;
Science, 2009; 326(5950):285-9
-
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.
Salazar-Gonzalez, J.F.; Bailes, E.; Pham, K.T.; Salazar, M.G.; Guffey, M.B.; Keele, B.F.; Derdeyn, C.A.; Farmer, P.; Hunter, E.; Allen, S.; Manigart, O.; Mulenga, J.; Anderson, J.A.; Swanstrom, R.; Haynes, B.F.; Athreya, G.S.; Korber, B.T.; Sharp, P.M.; Shaw, G.M.; Hahn, B.H.;
J Virol, 2008; 82(8):3952-70
-
HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure.
Manigart, O.; Courgnaud, V.; Sanou, O.; Valéa, D.; Nagot, N.; Meda, N.; Delaporte, E.; Peeters, M.; Van de Perre, P.;
AIDS, 2004; 18(12):1645-51
-
Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission.
Manigart, O.; Crepin, M.; Leroy, V.; Meda, N.; Valea, D.; Janoff, E.N.; Rouet, F.; Dequae-Merchadoux, L.; Dabis, F.; Rouzioux, C.; Van de Perre, P.; Diminution de la Transmission Mere-Enfant Study Group, .;
J Infect Dis, 2004; 190(8):1422-8
-
Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial.
Leroy, V.; Montcho, C.; Manigart, O.; Van de Perre, P.; Dabis, F.; Msellati, P.; Meda, N.; You, B.; Simonon, A.; Rouzioux, C.; DITRAME Study Group, .;
AIDS, 2001; 15(4):517-22
- → View all Olivier Manigart's publications
